Navigation Links
Diuretics Still Best Treatment for High Blood Pressure
Date:11/18/2009

Long-term comparison study finds chlorthalidone most likely to prevent heart failure, stroke

WEDNESDAY, Nov. 18 (HealthDay News) -- Tried-and-true diuretics maintain their status as the best first-line treatment in older men and women with high blood pressure, new research concludes.

The thiazide-type diuretic chlorthalidone outshone three other treatments -- a calcium channel blocker, an ACE inhibitor and an alpha-receptor blocker -- in most areas, especially in lowering the incidence of stroke and heart failure, according to the most current data from a large ongoing study known as ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).

"We believe thiazide-type diuretics should still be preferred," said study investigator Dr. William Cushman, professor and chief of preventive medicine at the Veterans Affairs Medical Center in Memphis, Tenn., at a news conference on the findings Wednesday at the annual meeting of the American Heart Association (AHA) in Orlando, Fla.

"The message is largely unchanged, and the main message is that treating hypertension [high blood pressure] is very necessary," added Dr. Clyde Yancy, president of the AHA. "Treating hypertension with chlorthalidone resulted in a significant reduction in heart failure and stroke."

The original trial, begun in 1994, involved more than 42,000 patients with hypertension and at least one other risk factor for cardiovascular disease. The participants were randomly assigned to take one of the following anti-hypertensive drugs: chlorthalidone (the diuretic), amlodipine besylate (the calcium channel blocker), doxazosin mesylate (the alpha blocker) or lisinopril (an ACE inhibitor).

The five-year follow-up, which ended in 2002, was intended to see if new differences emerged with long-term use of the medications, especially regarding coronary heart disease, total mortality, heart failure and aggregate cardiovascular disease.

"This is the largest hypertension trial to date," Cushman said.

Earlier results from ALLHAT had also found that diuretics were as good or better than other blood pressure-lowering drugs for treating hypertension in patients with metabolic syndrome (a collection of factors that put people at risk of heart disease), especially black patients.

"None of the newer drugs were superior to chlorthalidone for reducing death from cardiovascular disease or end-stage renal disease, although the calcium channel blocker was very similar," Cushman stated.

Strokes were much more common in black study participants taking the newer drugs, and patients on the calcium channel blocker had much higher rates of heart failure.

Cushman also presented some 10-year follow-up data, which were essentially the same as the five-year data. No new adverse events cropped up, he noted.

"Chlorthalidone treatment is superior to each in preventing one or more major cardiovascular events as long as participants continued taking the drug," he said.

More information

The American Heart Association has more on high blood pressure.



SOURCES: Nov. 18, 2009, news conference with William Cushman, M.D., professor and chief of preventive medicine, Veterans Affairs Medical Center, Memphis, Tenn.; Clyde Yancy, M.D., president, American Heart Association; Nov. 18, 2009, presentation, American Heart Association annual meeting, Orlando, Fla.


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Blood Pressure Pill Combo More Effective Than Diuretics
2. Diuretics excel in drug comparison trial involving hypertension/metabolic syndrome
3. Diuretics Best for Hypertension and Metabolic Syndrome
4. Doc Fix NOT What The Doctor Ordered; National Physician Group OPPOSES Pay Raise in House; Failed in Senate, Still a Bad Idea in the House; Payoff to AMA? New Survey Shows Money is Not Primary Concern of Doctors
5. LTC Awareness Month Finds Americans Still in Dark about Long-Term Care
6. Father Norman Weslin and Four Pro-Lifers Still in Jail.
7. Life Saving Estill Medical Technologies Receives Prestigious Dallas 100(TM) Award
8. Practical Nursing Still a Growth Area in BC
9. Antibiotic Resistance Still a Major Public Health Threat
10. Lying Still Raises Artificial Insemination Success
11. Laying Still Raises Artificial Insemination Success
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... Nursing Society (ONS) wanted to create a communications platform that positions them as ... goal, Elliance and ONS reinvented their online publication as an always-on, always-fresh news, ...
(Date:3/24/2017)... ... March 24, 2017 , ... Gastro ... their partnership to prep patients for colonoscopy at the HyGIeaCare® Center that is ... Ave., Miami, FL. , The HyGIeaCare® Prep, cleared by the U.S. ...
(Date:3/24/2017)... ... March 24, 2017 , ... “Vintage and Harvest A Cultivation of ... college Bible teacher residing in North Carolina with his wife, Anna Marie. He and ... with six grandchildren. David is also the author of “Shadow and Substance.” , “Love, ...
(Date:3/23/2017)... ... ... The physicians of KSF Orthopaedic Center PA are proud to announce the ... located at 2255 E. Mossy Oaks Rd., Suite 440, Spring, Texas 77389 inside the ... living in the north Houston area (The Woodlands, Conroe, Magnolia, Kingwood, Humble) with an ...
(Date:3/23/2017)... Holland, PA and Grimsby, Ontario (PRWEB) , ... March 23, 2017 , ... The MBI ... the modular industry or whose acts have had a significant impact on the careers of ... Sales and Marketing with NRB Inc. was inducted into the MBI’s Hall of Fame. ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... SAN DIEGO , March 24, 2017  GenomeDx ... (Genomics Resource Information Database) and Decipher® Prostate Cancer Classifier ... Annual European Association of Urology (EAU) Congress held March ... . The Annual EAU Congress is ... and most comprehensive research in the urological field. ...
(Date:3/24/2017)... BOTHELL, Wash. , March 23, 2017 /PRNewswire/ ... developer of advanced medical technology for non-invasive surgery, ... the Mirabilis System for treatment of uterine fibroids ... that it had received approval from the US ... study of the Mirabilis System in the United ...
(Date:3/24/2017)... The Board of Directors of Nordic Nanovector ASA ... the complete 2016 Annual Accounts with notes. The report is ... in the section Investor Relations/Reports and presentations/Annual Reports. ... For further information, ... Officer Cell: +47-91-51-95-76 Email: ir@nordicnanovector.com Media ...
Breaking Medicine Technology: